Tarsus Pharmaceuticals, Inc. TARS Operating lease liability
Operating lease liability at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept tars:DeferredTaxAssetsOperatingLeaseLiability.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-K, filed February 23, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s operating lease liability.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s operating lease liability?
- Tarsus Pharmaceuticals, Inc. (TARS) reported operating lease liability of $4.36M in Q4 2025.
- What does operating lease liability mean?
- This represents the total present value of future lease payments for operating assets, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased facilities and equipment necessary for operations. Monitoring this liability is essential for evaluating the company's fixed cost structure and overall financial leverage.